Design and characterization of Amoitone B-loaded nanostructured lipid carriers for controlled drug release

Figures & data

Figure 1. Chemical structure of Amoitone B.

Table 1. Preparation of AmB-NLC.

Sample	Amoitone B (mg)	GMS (mg)	MCT (mg)	SL (mg)
1	6	120	40	150
2	8	160	40	250
3	15	200	50	150
4	10	170	30	150
5	10	150	50	200
6	12	170	30	200
7	12	150	50	200
8	10	200	0	200

Figure 2. TEM image of AmB-NLC.

Figure 3. The size distribution of AmB-NLC.

Table 2. Results of AmB-NLC (n = 3).

Sample	Size (nm)	PI	Zeta potential (mV)	EE (%)	DL (%)
1	171.0 ± 7.7	0.308 ± 0.020	−15.2 ± 0.3	84.7 ± 0.74	3.18 ± 0.03
2	177.6 ± 0.2	0.319 ± 0.021	−22.8 ± 0.9	82.6 ± 0.26	3.30 ± 0.01
3	315.5 ± 14.6	0.369 ± 0.032	−18.6 ± 0.6	75.0 ± 0.58	4.50 ± 0.05
4	218.3 ± 4.5	0.266 ± 0.015	−19.0 ± 0.5	71.1 ± 0.55	3.56 ± 0.03
5	220.0 ± 2.9	0.313 ± 0.012	−20.4 ± 0.2	78.8 ± 0.33	3.94 ± 0.02
6	234.9 ± 2.0	0.287 ± 0.033	−18.6 ± 0.4	74.3 ± 0.59	4.46 ± 0.05
7	252.9 ± 7.2	0.327 ± 0.014	−19.6 ± 0.4	79.1 ± 0.76	4.74 ± 0.06
8	194.4 ± 3.8	0.276 ± 0.027	−20.0 ± 0.6	52.2 ± 0.34	2.61 ± 0.03

Figure 4. XRD spectra of Amoitone B (a), F68 (b), soybean lecithin (c), mannitol (d), GMS (e), the physical mixture (f), and the AmB-NLC freeze-dried powder (g).

Figure 5. DSC thermograms of Amoitone B (a), F68 (b), soybean lecithin (c), mannitol (d), GMS (e), the physical mixture (f), and the AmB-NLC freeze-dried powder (g).

Figure 6. In vitro drug release profiles of formulations with different liquid lipid content in PBS (pH7.4) (n = 3).